🍪 CompoundTalk uses cookies to improve your experience, analyze traffic, and personalize content. By continuing to use this site, you agree to our Cookie Policy.
Evidence-based GLP-1 & peptide discussion since 2023
ForumsInternationalBrazil ANVISA GLP-1 approvals — tirzepatide access update

Brazil ANVISA GLP-1 approvals — tirzepatide access update

lucas_SP_BR Fri, Mar 6, 2026 at 6:53 PM 7 replies 250 viewsPage 1 of 2
lucas_SP_BR
Member
456
1,890
Jun 2024
São Paulo, BR
Mar 6, 2026 at 8:18 PM#1

Can someone give me a current state of affairs on compounded tirzepatide as of Q1 2026? It feels like the landscape changes every week.

Last I heard, FDA removed tirzepatide from the shortage list in late 2024 and has been going after compounders. But I'm still seeing some pharmacies advertising it. What's the actual legal status? And what are people paying?

48 12NurseKim_ATL, paul_denver, TinaHashiRN and 45 others
Reply Quote Save Share Report
NurseKim_ATL
Senior Member
1,678
7,234
Feb 2024
Atlanta, GA
Mar 6, 2026 at 8:35 PM#2

Here's the current status as of March 2026:

Legal status: Complicated. FDA removed tirzepatide from the shortage list in October 2024 and has been issuing warning letters and cease-and-desist orders to compounders. HOWEVER, multiple lawsuits are challenging these enforcement actions, and some pharmacies have obtained temporary restraining orders allowing them to continue compounding.

Availability: Reduced but not eliminated. Several 503B facilities stopped voluntarily. Others are still compounding under legal protection from court orders. Some 503A pharmacies argue they're exempt from the enforcement because they compound on a patient-specific basis.

Pricing (where available):

  • Compounded tirzepatide 10mg vial: $150-275/month
  • Compounded tirzepatide 30mg vial: $300-450 (multi-month supply at lower doses)

Compare to brand Mounjaro/Zepbound at $1,050-1,200/month without insurance.

14 11raj_cambridge, ingrid_STO, pete_nash and 11 others
Reply Quote Save Share Report
labquiet_amy
Senior Member
1,234
6,789
Mar 2024
Cambridge, MA
Mar 6, 2026 at 8:52 PM#3

The key legal case right now is the litigation in the 5th Circuit involving the Outsourcing Facilities Association. The core argument is whether compounded tirzepatide using a different salt form constitutes an "essentially a copy" of branded Mounjaro/Zepbound. If the courts rule it's NOT a copy, compounding could resume broadly.

There's also a constitutional argument about FDA overreach in enforcement. Some pharmacies argue that FDA's administrative determination that the shortage ended is arbitrary and capricious because patients still can't access the medication due to cost.

It's a legal mess. But the practical takeaway: compounded tirzepatide is still available from some pharmacies, just fewer than before.

24 7LibrarianMeg, bri_stats, pete_manc_UK and 21 others
Reply Quote Save Share Report

PeptideMeter — Independent Peptide Analytics

Community-driven peptide testing and vendor rating platform. Transparent results. Unbiased analysis. Trusted by thousands.

View Results
JennaRN
Senior Member
1,987
8,923
Mar 2024
Colorado
Online
Mar 6, 2026 at 9:09 PM#4

So if I find a pharmacy still compounding it, am I taking any legal risk as a patient? Can FDA come after me for buying it?

Last edited: Mar 6, 2026 at 10:09 PM
46 22RegAffairsDC, BiostatsBrad, PeptideSynthNJ and 43 others
Reply Quote Save Share Report
mark_tokyo
Member
456
1,890
Jun 2024
Tokyo, JP
Mar 6, 2026 at 9:26 PM#5

No. FDA enforcement actions target pharmacies and prescribers, not patients. You are not breaking any law by filling a valid prescription for a compounded medication. The legal risk sits entirely with the pharmacy and potentially the prescriber.

That said, availability risk is real. If your pharmacy gets shut down mid-treatment, you're back to square one (see the "pharmacy shut down" thread).

Last edited: Mar 7, 2026 at 12:26 AM
6 19TrialNerd_Beth, HPLC_Greg, LibrarianMeg and 3 others
Reply Quote Save Share Report

Similar Threads

EU EMA compounding guidance — 2026 regulatory update9 replies
UK NHS GLP-1 prescribing — NICE TA875 and access guide7 replies
Australian TGA scheduling changes — peptide access 20268 replies
Canadian GLP-1 coverage — provincial formulary comparison6 replies
Purchasing GLP-1 in Mexico — legality, quality, and safety concerns6 replies
ForumsNewTrendingMembersAccount

Log In

Forgot password?
No account? Register